Loading...
•
Jun 30, 2022
Caribou Biosciences Q2 2022 Earnings Report
Reported financial results for the second quarter of 2022 and provided a business update.
Key Takeaways
Caribou Biosciences reported financial results for the second quarter of 2022, highlighting a strong financial position with $366.1 million in cash, cash equivalents, and marketable securities. The company made significant progress in advancing its pipeline of genome-edited allogeneic CAR-T and CAR-NK cell therapies, including encouraging initial clinical data from the Phase 1 ANTLER trial for CB-010.
Reported 6-month complete response (CR) in 3 of 6 patients across cohort 1 of the CB-010 ANTLER Phase 1 clinical trial.
Additional cohort 1 data expected by YE 2022; enrolling patients in cohort 2 of ANTLER trial.
CB-011 IND submission planned for Q4 2022 in patients with r/r MM.
CB-012 on track for 2023 IND submission in patients with r/r AML.
Revenue by Segment
Forward Guidance
Caribou Biosciences anticipates several milestones for 2022 and beyond, including sharing additional data from cohort 1 of the ANTLER Phase 1 trial for CB-010 by YE 2022, submitting an IND application for CB-011 in Q4 2022, announcing target selection for CB-020 in Q4 2022, and submitting an IND application for CB-012 in 2023.
Positive Outlook
- Plans to share additional data from cohort 1 of the ongoing ANTLER Phase 1 trial for CB-010 by YE 2022.
- Expects to submit an IND application for CB-011 in Q4 2022.
- Expects to announce target selection for CB-020 in Q4 2022.
- Expects to disclose armoring strategies under development for its CAR-NK cell platform in Q4 2022.
- Expects to submit an IND application for CB-012 in 2023.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...